RxDoctor Payments Data

Maureen Leehey

Neurology · Aurora, CONPI 1336258714

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $393 of the $606 with a category attached, or 64.8%. Sentynl Therapeutics, Inc. accounts for 64.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $563 and has fallen 99.9% since, to $1 in 2022. That places this record below the midpoint for neurology clinicians in CO, where the typical reported total is $699.

$606in general payments, 2019–2025

Across 6 payments — averaging $101.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sentynl Therapeutics, Inc.$393
  • Neurocrine Biosciences, Inc.$212
  • Travere Therapeutics, Inc.$1
$1,111,564in research payments, 2019–2025

Across 29 payments — averaging $38,330 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$920K
  • Mallinckrodt Hospital Products Inc.$86K
  • MDD US Operations, LLC$65K
  • Mallinckrodt Enterprises LLC$40K

What the payments were for

  • Consulting fees$39365%
  • Food & beverage$21235%
  • Education$10%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sentynl Therapeutics, Inc.1$393
Neurocrine Biosciences, Inc.4$212
Travere Therapeutics, Inc.1$1

How this compares

$606 in reported general payments places this provider in the 45th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Other neurology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →